These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28409559)

  • 1. Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.
    Wang HW; Xu ZK; Song Y; Liu YG
    Cancer Gene Ther; 2017 May; 24(5):215-220. PubMed ID: 28409559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling predicts response to temozolomide in malignant gliomas.
    Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
    Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas.
    Fan CH; Liu WL; Cao H; Wen C; Chen L; Jiang G
    Cell Death Dis; 2013 Oct; 4(10):e876. PubMed ID: 24157870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
    Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
    Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
    Remington M; Chtchetinin J; Ancheta K; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2009 Feb; 11(1):22-32. PubMed ID: 18812520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
    Ochsenbein AF; Schubert AD; Vassella E; Mariani L
    J Neurooncol; 2011 Jun; 103(2):343-51. PubMed ID: 20857319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
    Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
    Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
    Fukushima T; Takeshima H; Kataoka H
    Anticancer Res; 2009 Nov; 29(11):4845-54. PubMed ID: 20032445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
    Pan Q; Yang XJ; Wang HM; Dong XT; Wang W; Li Y; Li JM
    Cell Biochem Biophys; 2012 Jan; 62(1):185-91. PubMed ID: 21892781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methionine restriction of glioma does not induce MGMT and greatly improves temozolomide efficacy in an orthotopic nude-mouse model: A potential curable approach to a clinically-incurable disease.
    Kubota Y; Aoki Y; Masaki N; Obara K; Hamada K; Han Q; Bouvet M; Tsunoda T; Hoffman RM
    Biochem Biophys Res Commun; 2024 Feb; 695():149418. PubMed ID: 38176171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
    Kreth S; Thon N; Eigenbrod S; Lutz J; Ledderose C; Egensperger R; Tonn JC; Kretzschmar HA; Hinske LC; Kreth FW
    PLoS One; 2011 Feb; 6(2):e17156. PubMed ID: 21365007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population.
    Munisamy M; Munisamy S; Kumar JP; Jose A; Thomas L; Baburaj G; Subbiah V
    Pharmacogenomics J; 2021 Apr; 21(2):262-272. PubMed ID: 33589792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
    Younis SG; Khedr RA; El-Shorbagy SH
    J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research.
    Jiang G; Jiang AJ; Xin Y; Li LT; Cheng Q; Zheng JN
    Mol Biol Rep; 2014 Oct; 41(10):6659-65. PubMed ID: 24990698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases].
    Zhang JP; Shi HL; Sai K; Yue WY; Mu YG; Zhang XH; Chen ZP
    Ai Zheng; 2006 Dec; 25(12):1533-7. PubMed ID: 17166381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of temozolomide on immune response during malignant glioma chemotherapy.
    Sengupta S; Marrinan J; Frishman C; Sampath P
    Clin Dev Immunol; 2012; 2012():831090. PubMed ID: 23133490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
    Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
    J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.